Evaluation of CD3 and CD8 T-Cell Immunohistochemistry for Prognostication and Prediction of Benefit From Adjuvant Chemotherapy in Early-Stage Colorectal Cancer Within the QUASAR Trial
Journal of Clinical Oncology · 10.10.2024 · 42 (29) · 3430-3442
DOI: 10.1200/jco.23.02030 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.10.2024. Verfasst von Christopher J M Williams und 24 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pathology and Data Analytics, University of Leeds, Leeds, United Kingdom. Hauptthemen laut MEDLINE: Colorectal Neoplasms, CD3 Complex, Immunohistochemistry, CD8-Positive T-Lymphocytes. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
PURPOSE High densities of tumor infiltrating CD3 and CD8 T-cells are associated with superior prognosis in colorectal cancer (CRC). Their value as predictors of benefit from adjuvant chemotherapy is uncertain. PATIENTS AND METHODS Tumor tissue from 868 patients in the QUASAR trial (adjuvant fluorouracil/folinic acid v observation in stage II/III CRC) was analyzed by CD3 and CD8 immunohistochemistry. Pathologists, assisted by artificial intelligence, calculated CD3 and CD8 cell densities (cells/mm 2 ) in the core tumor (CT) and invasive margin (IM). Participants were randomly partitioned into training and validation sets. The primary outcome was recurrence-free interval (RFI), 2-year RFI for assessment of biomarker-treatment interactions. Maximum-likelihood methods identified optimal high-risk/low-risk group cutpoints in the training set. Prognostic analyses were repeated in the validation set. RESULTS In the training set, the recurrence rate in the high-risk group was twice that in the low-risk group for all measures (CD3-CT: rate ratio [RR], 2.00, P = .0008; CD3-IM: 2.38, P < .00001; CD8-CT: 2.17, P = .0001; CD8-IM: 2.13, P = .0001). This was closely replicated in the validation set (RR, 1.96, 1.79, 1.72, 1.72, respectively). In multivariate analyses, prognostic effects were similar in colon and rectal cancers, and in stage II and III disease. Proportional reductions in recurrence with adjuvant chemotherapy were of similar magnitude in the high- and low-recurrence risk groups. Combining information from CD3-IM and CD3-CT (CD3 Score) generated high-, intermediate-, and low-risk groups with numbers needed to treat (NNTs) to prevent one disease recurrence being 11, 21, and 36, respectively. CONCLUSION Recurrence rates in the high-risk CD3/CD8 groups are twice those in the low-risk groups. Proportional reductions with chemotherapy are similar, allowing NNTs derived in QUASAR to be updated using contemporary, nonrandomized data sets.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Pathology and Data Analytics, University of Leeds, Leeds, United Kingdom.
- Leeds Institute of Medical Research, University of Leeds, Leeds, United Kingdom.
- Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.
- Deceased.
- Roche Diagnostics Solutions, Clinical Development and Medical Affairs, Oro Valley, AZ.
- Roche Diagnostics Solutions, Imaging and Algorithms, Digital Pathology, Santa Clara, CA.
ORCID-Profile: Christopher J M Williams, Richard Gray, Michael Shires, Liping Zhang, Dongyao Yan, Michael Hale, Susan D Richman, Jenny F Seligmann, Nicholas P West, Kandavel Shanmugam, Philip Quirke
Zitieren
APA
Williams, C. J. M., Gray, R., Hills, R. K., Shires, M., Zhang, L., Zhao, Z., Gardner, T., Sapanara, N., Xu, X. M., Bai, I., Yan, D., Muranyi, A., Dance, S., Aghaei, F., Hemmings, G., Hale, M., Kurkure, U., Guetter, C., Richman, S. D., …, & Quirke, P. (2024). Evaluation of CD3 and CD8 T-Cell Immunohistochemistry for Prognostication and Prediction of Benefit From Adjuvant Chemotherapy in Early-Stage Colorectal Cancer Within the QUASAR Trial. Journal of Clinical Oncology, 42(29), 3430-3442. https://doi.org/10.1200/jco.23.02030
Vancouver
Williams CJM, Gray R, Hills RK, Shires M, Zhang L, Zhao Z, et al. Evaluation of CD3 and CD8 T-Cell Immunohistochemistry for Prognostication and Prediction of Benefit From Adjuvant Chemotherapy in Early-Stage Colorectal Cancer Within the QUASAR Trial. Journal of Clinical Oncology. 2024;42(29):3430-3442. doi:10.1200/jco.23.02030
BibTeX
@article{Williams2024,
author = {Williams, Christopher J M and Gray, Richard and Hills, Robert K and Shires, Michael and Zhang, Liping and Zhao, Zuo and Gardner, Tracie and Sapanara, Nancy and Xu, Xiao-Meng and Bai, Isaac and Yan, Dongyao and Muranyi, Andrea and Dance, Sarah and Aghaei, Faranak and Hemmings, Gemma and Hale, Michael and Kurkure, Uday and Guetter, Christoph and Richman, Susan D and Hutchins, Gordon and Seligmann, Jenny F and West, Nicholas P and Singh, Shalini and Shanmugam, Kandavel and Quirke, Philip},
title = {Evaluation of CD3 and CD8 T-Cell Immunohistochemistry for Prognostication and Prediction of Benefit From Adjuvant Chemotherapy in Early-Stage Colorectal Cancer Within the QUASAR Trial},
journal = {Journal of Clinical Oncology},
year = {2024},
volume = {42},
number = {29},
pages = {3430--3442},
doi = {10.1200/jco.23.02030}
}
EUVIMED